CN103772373B - 作为受体酪氨酸激酶抑制剂的喹唑啉类似物 - Google Patents

作为受体酪氨酸激酶抑制剂的喹唑啉类似物 Download PDF

Info

Publication number
CN103772373B
CN103772373B CN201310581100.3A CN201310581100A CN103772373B CN 103772373 B CN103772373 B CN 103772373B CN 201310581100 A CN201310581100 A CN 201310581100A CN 103772373 B CN103772373 B CN 103772373B
Authority
CN
China
Prior art keywords
alkyl
bases
quinazoline
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN201310581100.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103772373A (zh
Inventor
埃利·华莱士
乔治·托帕洛夫
约瑟夫·雷西卡托斯
亚历山大·巴克梅尔特
赵千
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/642,440 external-priority patent/US7501427B2/en
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN103772373A publication Critical patent/CN103772373A/zh
Application granted granted Critical
Publication of CN103772373B publication Critical patent/CN103772373B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201310581100.3A 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物 Expired - Lifetime CN103772373B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/642,440 US7501427B2 (en) 2003-08-14 2003-08-14 Quinazoline analogs as receptor tyrosine kinase inhibitors
US10/642,440 2003-08-14
US55171804P 2004-03-10 2004-03-10
US60/551,718 2004-03-10
CNA2004800264589A CN1852714A (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800264589A Division CN1852714A (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物

Publications (2)

Publication Number Publication Date
CN103772373A CN103772373A (zh) 2014-05-07
CN103772373B true CN103772373B (zh) 2017-06-09

Family

ID=34198338

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201310581100.3A Expired - Lifetime CN103772373B (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
CN201110283526.1A Expired - Lifetime CN102432552B (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
CN201310428856.4A Expired - Lifetime CN103664802B (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201110283526.1A Expired - Lifetime CN102432552B (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
CN201310428856.4A Expired - Lifetime CN103664802B (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物

Country Status (23)

Country Link
US (2) US7452895B2 (https=)
EP (1) EP1660090B1 (https=)
JP (1) JP4828421B2 (https=)
KR (2) KR100953246B1 (https=)
CN (3) CN103772373B (https=)
AR (1) AR045378A1 (https=)
AU (1) AU2004264937B2 (https=)
BR (1) BRPI0413565B8 (https=)
CA (1) CA2535614C (https=)
CL (1) CL2004002066A1 (https=)
CY (1) CY1113992T1 (https=)
DK (1) DK1660090T3 (https=)
ES (1) ES2399427T3 (https=)
IL (1) IL173593A (https=)
IS (1) IS8288A (https=)
MX (1) MXPA06001767A (https=)
NO (1) NO336275B1 (https=)
NZ (1) NZ545459A (https=)
PL (1) PL1660090T3 (https=)
PT (1) PT1660090E (https=)
RU (1) RU2350605C2 (https=)
TW (1) TWI353982B (https=)
WO (1) WO2005016346A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
DK1660090T3 (da) * 2003-08-14 2012-12-17 Array Biopharma Inc Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
ATE446294T1 (de) 2005-11-15 2009-11-15 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
WO2013056108A2 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Solid dispersion
AU2012323890A1 (en) 2011-10-14 2014-05-29 Array Biopharma Inc. Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them
EP3400943B1 (en) 2012-03-23 2020-12-02 Array Biopharma, Inc. Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
EP3344251B1 (en) 2015-09-04 2021-04-28 Aslan Pharmaceuticals PTE Limited A combination therapy comprising varlitinib and an anticancer agent
WO2017184086A1 (en) * 2016-04-21 2017-10-26 Aslan Pharmaceuticals Pte. Ltd. Method of treating liver cancer
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method
CN106317039A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106317040A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106349231A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一类含卤代噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106349230A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN106279135A (zh) * 2016-08-09 2017-01-04 浙江医药高等专科学校 一种噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
WO2018038684A1 (en) 2016-08-26 2018-03-01 Agency For Science, Technology And Research Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
TW201834649A (zh) 2017-03-02 2018-10-01 新加坡商亞獅康私人有限公司 癌症療法
BR112019022280A2 (pt) 2017-04-28 2020-05-19 Seattle Genetics Inc tratamento de cânceres de her2 positivo
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
EP4523755A3 (en) 2018-09-18 2025-06-11 F. Hoffmann-La Roche AG Quinazoline derivatives as antitumor agents
JP2022504201A (ja) * 2018-10-09 2022-01-13 アスラン ファーマシューティカルズ ピーティーイー リミテッド バリチニブのマロン酸塩
CN111499622B (zh) * 2019-07-08 2023-06-06 山东省科学院菏泽分院 一种治疗胆管癌的药物的制备方法
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
CR20230604A (es) 2021-06-26 2024-02-19 Array Biopharma Inc Inhibidores de mutación de her2
WO2023081637A1 (en) * 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
CN118715216A (zh) * 2022-03-28 2024-09-27 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
CN121969632A (zh) * 2023-09-27 2026-05-01 江苏恒瑞医药股份有限公司 一种喹唑啉衍生物的可药用盐、其结晶形式及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1211240A (zh) * 1996-02-14 1999-03-17 曾尼卡有限公司 作为抗肿瘤剂的喹唑啉衍生物
WO2001098277A2 (en) * 2000-06-22 2001-12-27 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583774A (en) 1948-04-30 1952-01-29 Merck & Co Inc Vitamin b6 derivatives
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5204348A (en) 1988-10-06 1993-04-20 Mitsui Toatsu Chemicals Inc. Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (https=) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
EP1028964A1 (en) 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
JP2002505288A (ja) * 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
US6017922A (en) 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
EA003786B1 (ru) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
IL144214A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
PT1154774E (pt) * 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2384282A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
ES2242723T3 (es) 2000-02-17 2005-11-16 Bristol-Myers Squibb Company Ligandos derivados de anilina para el receptor de la tiroides .
BR0111377A (pt) 2000-06-06 2003-06-03 Pfizer Prod Inc Derivados de tiofeno úteis como agentes anticancerìgenos
AU2001273071B2 (en) * 2000-06-30 2005-09-08 Glaxo Group Limited Quinazoline ditosylate salt compounds
WO2003015778A1 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US7169788B2 (en) 2001-10-30 2007-01-30 Merck & Co., Inc. Tyrosine kinase inhibitors
US20050043336A1 (en) * 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
WO2003055491A1 (en) * 2001-12-24 2003-07-10 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
CA2514479A1 (en) 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
PE20040945A1 (es) 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
BRPI0410720A (pt) 2003-05-27 2006-06-20 Pfizer Prod Inc quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
DK1660090T3 (da) 2003-08-14 2012-12-17 Array Biopharma Inc Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CA2536140A1 (en) 2003-08-18 2005-02-24 Pfizer Products Inc. Dosing schedule for erbb2 anticancer agents
JP2007510708A (ja) 2003-11-06 2007-04-26 ファイザー・プロダクツ・インク 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
ATE446294T1 (de) 2005-11-15 2009-11-15 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1211240A (zh) * 1996-02-14 1999-03-17 曾尼卡有限公司 作为抗肿瘤剂的喹唑啉衍生物
WO2001098277A2 (en) * 2000-06-22 2001-12-27 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A mild cyclodesulfurization of N-(2-hydroxyethyl)-N’-phenylthioureas to 2-phenylamino-2-oxazolines using TsCl/NaOH;Taek Hyeon Kim,等;《Tetrahedron》;20011231;第57卷;7137-7141 *
A Selective and Convenient Method for the Synthesis of 2-Phenylaminothiazolines;April L. Bernacki，等;《Organic Letters》;20101101;第12卷(第23期);5526-5529 *
Synthesis of N-benzothiazol-2-yl-amides by a copper-catalyzed intramolecular cyclization process;Junke Wang，等;《Tetrahedron Letters》;20071122;第49卷;467-470 *

Also Published As

Publication number Publication date
NZ545459A (en) 2009-12-24
AU2004264937B2 (en) 2010-04-29
US20090048279A1 (en) 2009-02-19
RU2006103493A (ru) 2007-09-20
DK1660090T3 (da) 2012-12-17
US8278314B2 (en) 2012-10-02
NO336275B1 (no) 2015-07-06
BRPI0413565B1 (pt) 2019-10-01
CN103664802B (zh) 2015-08-05
TWI353982B (en) 2011-12-11
IL173593A (en) 2011-11-30
TW200519096A (en) 2005-06-16
CN102432552A (zh) 2012-05-02
PL1660090T3 (pl) 2013-04-30
BRPI0413565A (pt) 2006-10-17
IS8288A (is) 2006-02-07
CA2535614C (en) 2009-12-22
CN103772373A (zh) 2014-05-07
EP1660090A4 (en) 2008-12-03
JP2007502295A (ja) 2007-02-08
CN102432552B (zh) 2016-01-20
EP1660090A1 (en) 2006-05-31
US7452895B2 (en) 2008-11-18
ES2399427T3 (es) 2013-04-01
KR20100018079A (ko) 2010-02-16
PT1660090E (pt) 2013-01-11
KR20060064630A (ko) 2006-06-13
EP1660090B1 (en) 2012-11-21
RU2350605C2 (ru) 2009-03-27
US20050043334A1 (en) 2005-02-24
CA2535614A1 (en) 2005-02-24
NO20061171L (no) 2006-04-10
IL173593A0 (en) 2006-07-05
KR100953246B1 (ko) 2010-04-16
WO2005016346A1 (en) 2005-02-24
HK1085400A1 (en) 2006-08-25
BRPI0413565B8 (pt) 2021-05-25
AR045378A1 (es) 2005-10-26
AU2004264937A1 (en) 2005-02-24
JP4828421B2 (ja) 2011-11-30
CY1113992T1 (el) 2016-07-27
MXPA06001767A (es) 2006-05-12
CL2004002066A1 (es) 2005-06-03
KR101028952B1 (ko) 2011-04-12
CN103664802A (zh) 2014-03-26

Similar Documents

Publication Publication Date Title
CN103772373B (zh) 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
AU2021326209B2 (en) EFGR inhibitor, preparation method therefor, and application thereof
CN101687822B (zh) 二(芳基氨基)芳基化合物
AU664496B2 (en) Quinazoline derivatives
ES2457396T3 (es) 3-Cianoquinolinas sustituidas como inhibidores de las proteínas tirosina quinasas
JP7337951B2 (ja) 癌を治療するための窒素含有芳香族ヘテロ環アミド誘導体
CN100412066C (zh) 用作蛋白激酶抑制剂的化合物和组合物
SK284846B6 (sk) Deriváty substituovaného 3-kyanochinolínu, spôsob ich prípravy, ich použitie a farmaceutický prostriedok s ich obsahom
EP1178966B1 (en) Quinoline derivatives as inhibitors of mek enzymes
CN107074874A (zh) Erk抑制剂
CN115057855B (zh) 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
KR20170031241A (ko) 시클린-의존성 키나제 (cdk) 억제제로서의 2-h-인다졸 유도체 및 그의 치료적 용도
CN102348708A (zh) 激酶抑制剂的前药形式及其在治疗中的用途
JP2015524448A (ja) アルキニルへテロ芳香環化合物及びその応用
EP1814545A2 (en) Compounds and compositions as protein kinase inhibitors
WO2012044090A2 (ko) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
CN108047205B (zh) 2-(2，4，5-取代苯氨基)嘧啶衍生物、其制备方法及其在制备抗肿瘤药物中的应用
CN102812010B (zh) 喹唑啉衍生物及其制备方法和应用
CN115746023B (zh) 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法
ZA200601333B (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
TW201738227A (zh) 一種稠環化合物、其製備方法和應用及其中間體化合物
JP2025526715A (ja) ピリジノピリミジノン化合物の結晶、その酸塩、その酸塩の結晶及び使用
KR20250041906A (ko) Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물
WO2024219619A1 (ko) Hpk1 및 mlk3 저해제 및 이를 함유하는 항암용 조성물
HK40082931B (en) Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20170609

CX01 Expiry of patent term